[English]  [Pусский]  [中文]  
ctt-journal > Kaplanov K.1 et al. (Abstract)

Kaplanov K.1 et al. (Abstract)

Cellular Therapy and Transplantation (CTT), Vol. 3, No. 12
doi: 10.3205/ctt-2011-No12-abstract13

© The Authors. This abstract is provided under the following license: Creative Commons Attribution 3.0 Unported

Abstract accepted for "5th Raisa Gorbacheva Memorial Meeting Hematopoietic Stem Cell Transplantation in Children and Adults", Saint Petersburg, Russia, September 18–20, 2011

Preliminary Program

Contribute a comment


Influence of imatinib mesylate concentration in the serum of patients with chronic myeloid leukemia on the achievement of the complete cytogenetic and major molecular responses 

Kamil D. Kaplanov1, Tatiana U. Klitochenko1, Elena G. Ovsannikova2

1GUZ “Volgograd Regional Clinical Oncology Dispensary N1”, Department of Hematology, Volgograd, Russia; 2Astrakhan State medical academy, Astrakhan, Russia

Correspondence: Kamil D.Kaplanov, GUZ "Volgograd Regional Clinical Oncology Dispensary N1", Department of Hematology, Zemliachky str., 78, Volgograd, 400138, Russia, E-mail: kamilos@spam is badmail.ru


Aim: To determine the effect of concentration of imatinib mesylate on the achievement of the cytogenetic and molecular responses in patients with chronic myeloid leukemia (CML) in chronic phase.

Materials and methods: The group of 87 patients with CML in the chronic phase was randomly formed. The concentration of imatinib in the blood serum was determined by means of high performance liquid chromatography with detection by tandem mass spectrometry. The influence of the concentration of imatinib on the achievement of the complete cytogenetic response (CCR) and major molecular response (MMR) was estimated in univariate tests and multivariate analysis.

The distribution of concentration average values of the imatinib mesylate in the blood serum of patients was subject to the normal distribution (p>0.05, Kolmogorov-Smirnov test). A logistic regression test showed a statistically significant effect of the concentration of imatinib on the chance to achieve CCR and MMR (p<0.01). The average concentration value in patients with complete cytogenetic response (n=60) was equal to 1,475.15 ± 95.5 ng/ml, compared to patients who didn’t achieve complete cytogenetic response (n=27), which was equal to 998.15 ± 115.7 ng/ml. The difference in average values of concentrations between groups is statistically significant (p=0.002, T-test). The average value of concentration in patients with MMR (n=47) was equal to 1,530.66 ± 97.6 ng/ml; in patients without MMR (n=40) it was equal to 1,087.95 ± 116.2 ng/ml. The difference in average values of concentrations between the groups was statistically significant (p=0.005, T-test).

Conclusion: Differences in concentrations of imatinib mesylate in serum may influence the effectiveness of the treatment of CML.

Keywords:  chronic myeloid leukemia, chronic phase, imatinib mesylate, cytogenetic response, molecular response